Landmark New England Journal Of Medicine Publication Reinforces Potential Of GSK's Respiratory Syncytial Virus Older Adult Vaccine Candidate
February 16, 2023
February 16, 2023
LONDON, England, Feb. 16 (TNSjou) -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on Feb. 15, 2023:
GSK plc (LSE/NYSE: GSK) today announced the publication of positive phase III trial results for its respiratory syncytial virus (RSV) older adult vaccine candidate in the New England Journal of Medicine. The publication summarises the pivotal efficacy data (previously presented at IDWeek 2022), showing the vaccine candidate met the primary endpoint o . . .
GSK plc (LSE/NYSE: GSK) today announced the publication of positive phase III trial results for its respiratory syncytial virus (RSV) older adult vaccine candidate in the New England Journal of Medicine. The publication summarises the pivotal efficacy data (previously presented at IDWeek 2022), showing the vaccine candidate met the primary endpoint o . . .